World Journal of Surgery

, Volume 30, Issue 4, pp 628–636 | Cite as

Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues

  • Yoshihisa Kinoshita
  • Katsuyuki Kuratsukuri
  • Steve Landas
  • Katsumi Imaida
  • Peter M. RovitoJr.
  • Ching Y. Wang
  • Gabriel P. Haas
Article

Abstract

Background

Prostate-specific membrane antigen (PSMA) is upregulated in androgen-dependent prostate carcinoma and it has been targeted for immunotherapy and diagnosis of this cancer. However, this protein is also expressed in other tissues. The objective of this study is to investigate its expression in normal and malignant human tissues.

Methods

Using monoclonal antibodies 24.4E6 (specific for residues 638–657) and 7E11.C5 (specific for the transmembrane domain of PSMA), immunohistochemical detection of PSMA was performed in surgical specimens.

Results

Prostate-specific membrane antigen was detected in the epithelium of prostate, urinary bladder, proximal tubules of kidney, liver, esophagus, stomach, small intestine, colon, breast, fallopian tubes and testicular seminiferous tubules, hippocampal neurons and astrocytes, ependyma, cortex and medulla of the adrenal gland, and ovary stroma. It was also detected in neoplasms of the prostate, kidney, urinary bladder, stomach, small intestine, colon, lung, adrenal gland, and testis. It was not detected in normal seminal vesicles or the lung.

Conclusions

These findings demonstrate that PSMA is widely distributed in normal tissues, and, depending on the tumors, its expression is up- or down-regulated, or unchanged. The broad distribution of PSMA may make it suitable for the diagnosis and therapy of a wide variety of tumors.

Notes

Acknowledgements

This study was supported in part by the NIH grant 1RO1AG21389-01 and by the Veterans Administration.

References

  1. 1.
    Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927–936PubMedGoogle Scholar
  2. 2.
    Israeli RS, Powell CT, Corr JG, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807–1811PubMedGoogle Scholar
  3. 3.
    Barrett AJ. Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Enzyme nomenclature. Recommendations 1992. Suppl 4: corrections and additions (1997). Eur J Biochem 1997;250:1–6PubMedCrossRefGoogle Scholar
  4. 4.
    Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749–537PubMedGoogle Scholar
  5. 5.
    Luthi-Carter R, Barczak AK, Speno H, et al. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998;286:1020–1025PubMedGoogle Scholar
  6. 6.
    Ghadge GD, Slusher BS, Bodner A, et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci USA 2003;100:9554–9559PubMedCrossRefGoogle Scholar
  7. 7.
    Yokoyama O, Mizuno H, Komatsu K, et al. Role of glutamate receptors in the development and maintenance of bladder overactivity after cerebral infarction in the rat. J Urol 2004;171:1709–1714PubMedGoogle Scholar
  8. 8.
    Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81–85PubMedGoogle Scholar
  9. 9.
    Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997;57:2321–2324PubMedGoogle Scholar
  10. 10.
    Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004;64:7995–8001PubMedCrossRefGoogle Scholar
  11. 11.
    Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591–4601PubMedCrossRefGoogle Scholar
  12. 12.
    Babaian RJ, Sayer J, Podoloff DA, et al. Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. J Urol 1994;152:1952–1955PubMedGoogle Scholar
  13. 13.
    Gala JL, Loric S, Guiot Y, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res 2000;6:4049–4054PubMedGoogle Scholar
  14. 14.
    Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192–3198PubMedGoogle Scholar
  15. 15.
    Dakappagari NK, Douglas DB, Triozzi PL, et al. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000;60:3782–3789PubMedGoogle Scholar
  16. 16.
    Kinoshita Y, Kuratsukuri K, Newman N, et al. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer. Prostate Cancer Prostatic Dis 2005;8:359–363PubMedCrossRefGoogle Scholar
  17. 17.
    Kuratsukuri K, Sone T, Wang CY, et al. Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. Int J Cancer 2002;102:244–249PubMedCrossRefGoogle Scholar
  18. 18.
    Sone T, Zukowski K, Land SJ, et al. Characteristics of a purified dog hepatic microsomal N,O-acyltransferase. Carcinogenesis 1994;15:595–599PubMedGoogle Scholar
  19. 19.
    Luthi-Carter R, Berger UV, Barczak AK, et al. Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci USA 1998;95:3215–3220PubMedCrossRefGoogle Scholar
  20. 20.
    Bzdega T, Turi T, Wroblewska B, et al. Molecular cloning of a peptidase against N-acetylaspartylglutamate from a rat hippocampal cDNA library. J Neurochem 1997;69:2270–2277PubMedGoogle Scholar
  21. 21.
    Bacich DJ, Pinto JT, Tong WP, et al. Expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 2001;12:117–123PubMedCrossRefGoogle Scholar
  22. 22.
    Murphy GP, Greene TG, Tino WT, et al. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 1998;160:2396–2401PubMedGoogle Scholar
  23. 23.
    Murphy GP, Kenny GM, Ragde H, et al. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology 1998;51:89–97PubMedGoogle Scholar
  24. 24.
    Su SL, Huang IP, Fair WR, et al. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 1995;55:1441–1443PubMedGoogle Scholar
  25. 25.
    Grauer LS, Lawler KD, Marignac JL, et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM′ protein in the LNCaP prostatic carcinoma cell line. Cancer Res 1998;58:4787–4789PubMedGoogle Scholar
  26. 26.
    Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53:227–230PubMedGoogle Scholar
  27. 27.
    Schmittgen TD, Teske S, Vessella RL, et al. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003;107:323–329PubMedCrossRefGoogle Scholar
  28. 28.
    Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528–539PubMedGoogle Scholar
  29. 29.
    O’Keefe DS, Bacich DJ, Heston WD. Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 2004;58:200–210PubMedGoogle Scholar
  30. 30.
    Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated alpha-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem 1999;274:8470–8483PubMedCrossRefGoogle Scholar
  31. 31.
    Sokoloff RL, Norton KC, Gasior CL, et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000;43:150–157PubMedCrossRefGoogle Scholar
  32. 32.
    Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 1995;62:552–558PubMedGoogle Scholar
  33. 33.
    Dumas F, Gala JL, Berteau P, et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer 1999;80:799–803PubMedCrossRefGoogle Scholar
  34. 34.
    Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greater in prostate adenocarcinoma and lymph node metastasis. Urology 1998;52:637–640PubMedCrossRefGoogle Scholar
  35. 35.
    Fracasso G, Bellisola G, Cingarlini S, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53:9–23PubMedCrossRefGoogle Scholar
  36. 36.
    Mincheff M, Tchakarov S, Zoubak S, et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial. Eur Urol 2002;38:208–217Google Scholar

Copyright information

© Société Internationale de Chirurgie 2006

Authors and Affiliations

  • Yoshihisa Kinoshita
    • 1
    • 2
  • Katsuyuki Kuratsukuri
    • 1
    • 2
  • Steve Landas
    • 3
  • Katsumi Imaida
    • 4
  • Peter M. RovitoJr.
    • 1
  • Ching Y. Wang
    • 1
  • Gabriel P. Haas
    • 1
    • 5
  1. 1.Department of UrologySUNY Upstate Medical UniversitySyracuseUSA
  2. 2.Department of UrologyOsaka City University Medical SchoolAbeno kuJapan
  3. 3.Department of PathologySUNY Upstate Medical UniversitySyracuseUSA
  4. 4.Department of Pathology and Host Defense, Faculty of MedicineKagawa UniversityJapan
  5. 5.VA Medical Center Irving AvenueSyracuseUSA

Personalised recommendations